Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA).

Maanasa Bandla Matthew David HowardA McNallyD ArmstrongI SimpsonA Mar

Published in: The Australasian journal of dermatology (2023)

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis presenting primarily with pulmonary and cutaneous features. The disease is typically seen in the fifth or sixth decade of life (1, 2). We report a case of EGPA in an adolescent who was successfully treated with the interleukin-5 (IL-5) receptor inhibitor, benralizumab.

Keyphrases

young adults
chronic rhinosinusitis
emergency department
intensive care unit
pulmonary hypertension
mental health
case report
combination therapy
replacement therapy
binding protein